In this interview, Anas Younes, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the two abstracts that in his opinion are practice-changing in the areas of T-cell lymphoma and chronic lymphocytic leukemia (CLL), presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. These are the ECHELON-2 (NCT01777152) clinical trial results, focusing on the use of brentuximab vedotin and CHP in peripheral T-cell lymphomas, and the data on the use of ibrutinib and rituximab for the frontline treatment of CLL.